By a show of hands, how many of you reading this article use a mobile app to manage your health? The term digital health has gradually become part of our lives, maybe more than you realize. It allows us to schedule appointments, view our medical records and test results, consult with our healthcare professionals, control our exercise routines, closely monitor health conditions, pay our medical bills, and so much more. Many of these tasks are accessible via mobile apps on smartphones and smart watches; but what exactly is digital health and how does this emerging model for delivering health care intersect with traditional forms of administering therapies to patients?
Listen to ASPET President, Dr. Carol Beck, give updates on ASPET 2025 registration, ASPET’s mentoring programs and more!
Last month, I focused on the value and importance of ASPET Divisions. When you become a member of ASPET, you receive free membership in at least one of our 10 divisions. While absolutely a critical reason to become an ASPET member, this is just one of many benefits of membership to consider as you receive our annual reminders to renew your membership for 2025.
The American Society for Pharmacology and Experimental Therapeutics’ (ASPET) Biotech Taskforce (BTF) was established in October 2023 to focus on increasing private sector participation within the Society.
A Conversation with ASPET’s Chair, Drug Metabolism and Disposition
Division, Kerry Goralski, PhD
Updates from some of our outstanding ASPET members.
This month The Pharmacologist features two new policy briefs written by participants of the 2024 ASPET Washington Fellows program. These topics present compelling arguments for policy improvements on an issue of personal importance to each Fellow. The policy briefs below discuss promoting housing among the homeless with substance abuse disorder and the federal legalization of Fentanyl test strips.
A showcase of early-career scientists—what drives them and why pharmacology is important to them.
The late Dr. V. Craig Jordan, CMG, OBE, DSc, PhD, FMedSci, FBPhS, FASPET, was an ASPET member for 44 years. He passed away on June 9 at the age of 76. Considered the “Father of Tamoxifen,” Dr. Jordan was a science researcher and professor at The University of Texas MD Anderson Cancer Center. He was an American and British pharmacologist who is credited with discovering the first targeted therapy in cancer to treat breast cancer and osteoporosis. His work uncovered that tamoxifen and other compounds that selectively target estrogen receptors could both treat and prevent breast cancer. Recognized for his work in breast cancer research, he led a Tamoxifen Team that specialized in drugs for breast cancer treatment and prevention.
Listen to ASPET President, Dr. Carol Beck, give updates on the ASPET IDEA Faculty Scholars Program, the Member-Get-A-Member program, updates on the Divisions and more!
